Ravi Salgia to Carcinoma, Small Cell
This is a "connection" page, showing publications Ravi Salgia has written about Carcinoma, Small Cell.
Connection Strength
6.215
-
A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. Adv Exp Med Biol. 2014; 799:85-117.
Score: 0.451
-
Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer. Mol Cancer Ther. 2014 Mar; 13(3):576-84.
Score: 0.449
-
Etoposide and temozolomide in combination for the treatment of progressive small-cell lung cancer central nervous system metastases: two cases. Tumori. 2013 Mar-Apr; 99(2):e73-6.
Score: 0.425
-
Non-receptor tyrosine kinase inhibitors in lung cancer. Anticancer Agents Med Chem. 2007 Nov; 7(6):633-42.
Score: 0.294
-
Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br J Cancer. 2007 Aug 06; 97(3):368-77.
Score: 0.289
-
A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res. 2007 Apr 15; 67(8):3529-34.
Score: 0.283
-
Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer. Lung Cancer. 2006 Nov; 54(2):243-5.
Score: 0.271
-
Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. Anticancer Res. 2004 Mar-Apr; 24(2C):1031-8.
Score: 0.228
-
Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small cell lung cancer. J Environ Pathol Toxicol Oncol. 2004; 23(4):237-51.
Score: 0.225
-
Small cell lung cancer: from molecular biology to novel therapeutics. J Exp Ther Oncol. 2003 Nov-Dec; 3(6):305-18.
Score: 0.223
-
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 2003 Oct 01; 63(19):6272-81.
Score: 0.222
-
Recent advances in the molecular biology, diagnosis and novel therapies for various small blue cell tumors. Anticancer Res. 2003 Jul-Aug; 23(4):3379-96.
Score: 0.218
-
Small-cell cancers, and an unusual reaction to chemotherapy. Case 1. Extrapulmonary small-cell carcinoma arising in the prostate. J Clin Oncol. 2003 Jun 15; 21(12):2437-8.
Score: 0.217
-
Fibronectin enhances viability and alters cytoskeletal functions (with effects on the phosphatidylinositol 3-kinase pathway) in small cell lung cancer. J Cell Mol Med. 2003 Apr-Jun; 7(2):157-64.
Score: 0.214
-
Molecular and cellular biology of small cell lung cancer. Semin Oncol. 2003 Feb; 30(1):57-71.
Score: 0.212
-
Role of receptor tyrosine kinases in lung cancer. Methods Mol Med. 2003; 74:113-25.
Score: 0.210
-
Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer. Oncologist. 2003; 8(1):69-75.
Score: 0.210
-
Circulating tumor cells and serum tumor biomarkers in small cell lung cancer. Anticancer Res. 2003 Jan-Feb; 23(1A):49-62.
Score: 0.210
-
Mechanisms of metastasis as related to receptor tyrosine kinases in small-cell lung cancer. J Environ Pathol Toxicol Oncol. 2003; 22(3):147-65.
Score: 0.210
-
Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer. J Cell Mol Med. 2002 Oct-Dec; 6(4):539-53.
Score: 0.207
-
Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res. 2002 Feb; 8(2):620-7.
Score: 0.197
-
Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene. 2000 Jul 20; 19(31):3521-8.
Score: 0.177
-
Molecular abnormalities in lung cancer. J Clin Oncol. 1998 Mar; 16(3):1207-17.
Score: 0.150
-
MET as a target for treatment of chest tumors. Lung Cancer. 2009 Feb; 63(2):169-79.
Score: 0.077
-
Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol. 2008 Feb 20; 26(6):870-6.
Score: 0.075
-
Biology and novel therapeutics for neuroendocrine tumors of the lung. J Biol Regul Homeost Agents. 2004 Jul-Dec; 18(3-4):275-90.
Score: 0.058
-
Reliable and sensitive identification of occult tumor cells using the improved rare event imaging system. Clin Cancer Res. 2004 May 01; 10(9):3020-8.
Score: 0.058
-
Targeted molecules in small cell lung cancer. Semin Oncol. 2004 Feb; 31(1 Suppl 1):106-11.
Score: 0.057
-
Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5880-7.
Score: 0.056
-
Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility. Oncogene. 1999 Jan 07; 18(1):67-77.
Score: 0.040